This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

51/100

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

Of 822 individuals enrolled in the HEAD study, 681 participants spanning cognitively unimpaired to dementia were included. Mean (SD) age was 69.3 (8.4) years, and 367 participants (53.9%) were female. The harmonized 5-class framework achieved excellent interrater agreement (κ = 0.77-0.85) and good to excellent intertracer agreement, highest between 18F-MK-6240 and 18F-flortaucipir (κ = 0.88). Compared with the regulatory-approved framework, the harmonized classification identified more tau-positive cognitively unimpaired participants (regulatory-approved binary: 26 of 364 participants; harmonized 18F-flortaucipir: 49 of 364 [PR = 1.89; 95% CI, 1.31-2.70; P = .001]; harmonized 18F-MK-6240: 71 of 364 [PR = 2.73; 95% CI, 1.95-3.83; P < .001]) and those with mild cognitive impairment (regulatory-approved binary: 100 of 223; harmonized 18F-flortaucipir: 123 of 223 [PR = 1.23; 95% CI, 1.12-1.35; P < .001]; harmonized 18F-MK-6240: 142 of 223 [PR = 1.42; 95% CI, 1.27-1.59; P < .001]), with convergence in dementia. Tau burden classes showed stepwise worsening of cognition, Aβ PET burden, and plasma p-tau217, with 1.4-fold, 3.2-fold, and 2.5-fold differences between the low and high tau classes, respectively. Conclusions and Relevance: In this prospective multitracer cross-sectional study, a 5-class harmonized tau PET visual reading framework showed high interrater and intertracer agreement and detected more early-stage tau pathology than the regulatory-approved binary approach, with tau burden classes tracking stepwise with cognition and biomarkers. These findings support a standardized, tracer-agnostic framework for diagnostic categorization, therapeutic window identification, and clinical trial stratification.

Key findings

Of 822 individuals enrolled in the HEAD study, 681 participants spanning cognitively unimpaired to dementia were included.
Mean (SD) age was 69.3 (8.4) years, and 367 participants (53.9%) were female.
The harmonized 5-class framework achieved excellent interrater agreement (κ = 0.77-0.85) and good to excellent intertracer agreement, highest between 18F-MK-6240 and 18F-flortaucipir (κ = 0.88).
Compared with the regulatory-approved framework, the harmonized classification identified more tau-positive cognitively unimpaired participants (regulatory-approved binary: 26 of 364 participants; harmonized 18F-flortaucipir: 49 of 364 [PR = 1.89; 95% CI, 1.31-2.70; P = .001]; harmonized 18F-MK-6240: 71 of 364 [PR = 2.73; 95% CI, 1.95-3.83; P < .001]) and those with mild cognitive impairment (regulatory-approved binary: 100 of 223; harmonized 18F-flortaucipir: 123 of 223 [PR = 1.23; 95% CI, 1.12-1.35; P < .001]; harmonized 18F-MK-6240: 142 of 223 [PR = 1.42; 95% CI, 1.27-1.59; P < .001]), with convergence in dementia.
Tau burden classes showed stepwise worsening of cognition, Aβ PET burden, and plasma p-tau217, with 1.4-fold, 3.2-fold, and 2.5-fold differences between the low and high tau classes, respectively.

Why it matters

This study developed a standardized visual reading framework for tau PET scans that identified more tau-positive people in early disease stages compared to the currently approved method. It is a diagnostic staging tool and does not test any treatment, cure, or prevention.

New to this subject? Start with our plain-English guide: Brain scans & tests →

Study details

Study designcross-sectional
Participants681
Effect size53.9%
Evidence strengthModerate

How this study scored 51/100

Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 49 of the 96 points we could judge it on, which is 51 out of 100.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (JAMA Neurology)
Journal's citation record	2 / 4	JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29)
Study design	4 / 12	A snapshot of people at one point in time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	5 / 5	2026 — within 1 year(s) of the newest study here
Sample size	2 / 4	681 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 2 year(s) since 2026
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Paolo Vitali holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record	2 / 3	Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 18 institution(s) in 5 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 42766299)
Free to read	2 / 2	Free to read
Points	49 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 49 of the 96 points we could judge it on is 51 out of 100.
Total	51 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Ruppert, E., Vermeiren, M. R., Medeiros, M. S., Povala, G., Soares, C., Rocha, A., et al. (2026). A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.3253

Vancouver

Ruppert E, Vermeiren MR, Medeiros MS, Povala G, Soares C, Rocha A, et al. A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease. JAMA Neurology. 2026. doi:10.1001/jamaneurol.2026.3253. PMID: 42766299.

BibTeX

@article{ruppert2026-42766299,
  author  = {Ruppert, Emma and Vermeiren, Marie R. and Medeiros, Marina Scop and Povala, Guilherme and Soares, Carolina and Rocha, Andreia and Franco, Álvaro de Oliveira and Rodrigues, Matheus Scarpatto and others},
  title   = {{A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease}},
  journal = {JAMA Neurology},
  year    = {2026},
  doi     = {10.1001/jamaneurol.2026.3253},
  pmid    = {42766299},
  url     = {https://doi.org/10.1001/jamaneurol.2026.3253}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Related studies in Brain scans and imaging

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →